These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33647240)

  • 1. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
    Kitagawa J; Arai H; Iida H; Mukai J; Furukawa K; Ohtsu S; Nakade S; Hikima T; Haranaka M; Uemura N
    Clin Transl Sci; 2021 Sep; 14(5):1967-1976. PubMed ID: 33982445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32992777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters.
    Mohos V; Fliszár-Nyúl E; Ungvári O; Bakos É; Kuffa K; Bencsik T; Zsidó BZ; Hetényi C; Telbisz Á; Özvegy-Laczka C; Poór M
    Drug Metab Dispos; 2020 Oct; 48(10):1064-1073. PubMed ID: 32661014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Sheltzer JM; Kjolby M; Pöhlmann S
    bioRxiv; 2020 Aug; ():. PubMed ID: 32793911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
    Blank A; Meier K; Urban S; Haefeli WE; Weiss J
    Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds.
    Theile D; Wagner L; Haefeli WE; Weiss J
    Eur J Pharm Sci; 2021 Jul; 162():105826. PubMed ID: 33813039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
    Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
    Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
    Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
    Weiss J; Theile D; Dvorak Z; Haefeli WE
    Pharmaceutics; 2014 Dec; 6(4):632-50. PubMed ID: 25521244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
    Rendic SP
    Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.
    Gupta A; Mugundu GM; Desai PB; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2008 Jun; 36(6):1172-80. PubMed ID: 18332086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.